论文部分内容阅读
美国 FDA 批准了 Schering-Plough 公司的一日一次口服无镇静作用的抗组胺药Claritin(loratadine 氯雷他定),用于季书性过敏性鼻炎的鼻部或非鼻部症状。本品已在70多个国家中销售。1992年的销售额达1.39亿美元,同时在13个国家可作非处方
The U.S. FDA approved Schering-Plow’s once-daily, oral, non-sedating anti-histamine Claritin (loratadine) for nasal or non-nasal symptoms of seasonal allergic rhinitis. This product has been sold in more than 70 countries. Sales in 1992 amounted to 139 million U.S. dollars and were non-prescription in 13 countries